Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | MRD-guided therapy in multiple myeloma

Benjamin Derman • 1 Jun 2022
EHA 2022
Multiple Myeloma

Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease (MRD)-guided therapy in multiple myeloma, highlighting key clinical trials using MRD to guide discontinuation of maintenance therapy and explaining the importance of better understanding how to both escalate and de-escalate therapy in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria for advisory board fees from Janssen, Sanofi, and COTA healthcare.

More from Benjamin Derman

The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma 4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023
MRD-guided treatment cessation in multiple myeloma 3:43
MRD-guided treatment cessation in multiple myeloma
Benjamin Derman • 1 Dec 2023
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial 9:57
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial
Benjamin Derman • 1 Dec 2023
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd 5:25
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd
Benjamin Derman • 1 Jun 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals